Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis - sprookjes - yvandenbroek - TriplyDB

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

http://www.wikidata.org/entity/Q33821257

about

Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication Barriers to a cure for HIV in women Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges Preventing HIV infection: pre-exposure and postexposure prophylaxis Antiretroviral pharmacology in mucosal tissues Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077 A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel HIV-prevention science at a crossroads: advances in reducing sexual risk.Clinical parameters essential to methodology and interpretation of mucosal responses Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.Bacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark Advances in the Development of Microbicides for the Prevention of HIV Infection.Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection.Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis Treatment to prevent transmission of HIV-1 Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.Zidovudine and Lamivudine for HIV Infection.Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.Reproductive assistance in HIV serodiscordant couples.HIV treatment as prevention: the utility and limitations of ecological observation.HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.Expression and localization of p-glycoprotein, multidrug resistance protein 4, and breast cancer resistance protein in the female lower genital tract of human and pigtailed macaque.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study)Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.

P2860

Q24634299-D952E853-C508-4595-B38D-D23592A076BF Q26768632-FAF30B3D-F027-47DA-BC74-652949C82642 Q26825641-65AAB006-5FC0-4F45-9C5B-7F2C10418305 Q26828445-E453F9DA-FBC2-4914-9450-BC5E4791E125 Q27014675-AB2C1AFA-032B-4D00-84DE-317B8C69B065 Q27300707-86F6DE7A-938B-4666-94B3-B298003C3AC1 Q28081272-704174F3-3F9C-407E-8926-1949C969390D Q28476730-A055EB0C-13AF-42FF-9816-E857EE17186B Q28485356-7FA697B2-0472-4110-8BCF-DD4523CA6278 Q28541918-B86A713F-D20A-4B6D-B345-1983E079B329 Q28743616-CAB15D38-F2AE-4EAF-89F6-ED57F28CBE3B Q30378142-0A5CDD43-6D8C-4D6A-9751-4154AF731152 Q30398452-0D8E5F69-0ACC-4053-836B-A3302E9A03A3 Q30744184-625E9926-4F95-4F79-9F36-0A4314F86892 Q33686465-21E4FE42-0A2F-4280-8347-9E74237A7560 Q33750075-C741D611-B80E-4BAB-B8E7-BB36DC56E9B5 Q33762924-3F47A780-FCD1-4489-AB4A-7F0B0BA87435 Q33769971-C36B86E1-E9D2-48E3-BC4A-F73049978583 Q33779372-2F8684BA-FFEF-4498-9035-D73E1AF36AB2 Q33798045-62AA648A-7484-415B-9667-3E8B8FE51D39 Q33821263-4EE416C3-553C-41EF-AE54-B9EC8BFA25A7 Q33888718-4FE83988-0A1E-49F8-946E-EFF98CD981F3 Q34021932-2E5A48F1-6BE3-48F2-8046-9EED775AAAAA Q34030735-C85FCE02-CB7D-4B4D-9CA7-7BBD63A67FA0 Q34085477-992B772B-964C-43A1-8B47-356B82599693 Q34102424-5291A068-228E-4950-9A21-FBA1C75E2913 Q34178412-B35AD788-3D15-4FE4-B1E5-3CD974505824 Q34194561-490ACB1E-4DD7-4E7E-853B-9DCD74FE5E7C Q34203175-9CAA104B-336D-4546-A469-3D3A870FF8E7 Q34311329-B9C98113-8708-4F37-87CF-98856B4F203E Q34339533-0A4CAB21-AB08-4528-BF7C-AC3BA9A4088C Q34366639-44F11FA8-9681-4919-9B40-6AB07C89AEFF Q34420654-75F8FD2D-421B-4A1A-86EC-C0A0BB360B13 Q34481359-60B2184A-1608-43D9-83E6-002986AA2A3D Q34506545-B3A579E5-D599-4B3C-A7ED-6FCD87D95A2B Q34737260-02D75CA4-EF68-4C1B-88B6-8EAC780B0EEC Q34834065-B2CD76AA-B9AB-426E-8101-18A2A0231B33 Q35005146-A1EF8516-10C6-4C65-853F-30D8C19DBBFD Q35102123-03C8223C-7239-4140-B6C5-03D3DDD04399 Q35119784-ECFD00E8-62F2-4F87-AD68-914B8BBDDF5E

P2860

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

http://www.wikidata.org/entity/Q33821257

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@ast

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@en

type

label

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@ast

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@en

prefLabel

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@ast

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@en

P1433

Q33821257-07EC2FB1-D9DC-45BF-A950-DA2510F4C356

P1476

Q33821257-04080FBC-DDCF-4E27-BAE5-297DFD1DF487

P2093

Q33821257-0DA90325-637E-47F2-A7DC-CE010CAA721E

Q33821257-1BB7B542-86B8-452A-9253-2ABA605A38D4

Q33821257-3CE60887-4638-4DDF-A002-881A343375CC

Q33821257-4EF81E64-5B4B-4B59-9939-078D6D6BC85A

Q33821257-71D2F5A4-C639-42DE-AABE-087C468D2BBE

Q33821257-B38082DF-6E11-4D9A-9FC9-03CBC28F3096

Q33821257-B84F6FAA-9296-4506-8E1F-976EF8D8B957

Q33821257-C1B625F5-2D78-4311-A7C5-207EE8EAFAF5

Q33821257-E93ACF68-D271-4478-B8CB-4CBB7AB5EE46

P2860

Q33821257-0C1B24BC-5B1C-4564-A96B-3F9E4CD0FEF4

Q33821257-12AD0DEA-305E-4BE1-B457-966386A5D9F5

Q33821257-18544663-088D-40A7-B15A-F6FFB18A6812

Q33821257-213E085C-FD9D-4461-B98C-9FAAB15858C8

Q33821257-2EAF3DC5-9AE6-42B6-8961-CD73EE99A580

Q33821257-557F7C55-4182-43F8-8D61-B6016E3DB710

Q33821257-6DCC1E05-72A5-4EF5-802D-8F98DF29CA79

Q33821257-721A92ED-21AC-457A-B126-AFF84194D3B0

Q33821257-732CE1EF-48A6-4BCB-9A42-E90E0FE1BC30

Q33821257-7DE3DD69-2239-4250-9B94-73891D507370

P304

Q33821257-06D5AA6F-485D-4476-BD31-BEA819C12EEC

P31

Q33821257-5C7E91DC-5DE9-465A-B107-94D15F8629EA

P356

Q33821257-CA33BB2F-681C-43AD-9BFB-48DBD40CCC3A

P407

Q33821257-C6646ABE-BC6A-4ABE-AF40-48697E08585B

P433

Q33821257-28F4AB5E-0C99-46C6-8038-45E46B6B548A

P478

Q33821257-B2713E3A-4A35-4065-ABC6-480203516861

P50

Q33821257-FA2D8271-BB71-4EAE-B6F1-2A05707298C8

P577

Q33821257-7E3792FA-C308-43CA-81A0-681B69133170

P698

Q33821257-47211E90-B35F-449C-972B-5EC9B17551F5

P921

Q33821257-A4A35E63-B884-4544-ABE0-5F8B5BA49BFB

P932

Q33821257-9257AEEB-5A90-4F76-97A5-1D907D7854FB

P356

QAD.0B013E328270385A

P1433

P1476

Antiretroviral drug exposure i ...... and post-exposure prophylaxis

@en

P2093

Amanda H Corbett

http://www.w3.org/2001/XMLSchema#string

Angela D M Kashuba

http://www.w3.org/2001/XMLSchema#string

Arlene S Bridges

http://www.w3.org/2001/XMLSchema#string

Byung Hwa Jung

http://www.w3.org/2001/XMLSchema#string

Julie B Dumond

http://www.w3.org/2001/XMLSchema#string

Kristine B Patterson

http://www.w3.org/2001/XMLSchema#string

Naser L Rezk

http://www.w3.org/2001/XMLSchema#string

Paul W Stewart

http://www.w3.org/2001/XMLSchema#string

Rosa F Yeh

http://www.w3.org/2001/XMLSchema#string

P2860

Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1?

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment

Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

Development and validation of a PCR-based enzyme-linked immunosorbent assay with urine for use in clinical research settings to detect Trichomonas vaginalis in women

Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy

HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis.

Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

P304

1899-1907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E328270385A

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17721097

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2862268

http://www.w3.org/2001/XMLSchema#string